Literature DB >> 26980218

Commentary: How do haematopoietic cell transplants cure leukaemia?

Mine Harada1,2, Robert Peter Gale3.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26980218     DOI： 10.1007/s12185-016-1969-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Evaluating Discrimination of Risk Prediction Models: The C Statistic.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  JAMA       Date:  2015-09-08       Impact factor: 56.272

2.  Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Authors:  Robert Peter Gale; John M Goldman
Journal:  Acta Haematol       Date:  2013-06-13       Impact factor: 2.195

3.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

Review 4.  Should persons with acute myeloid leukemia have a transplant in first remission?

Authors:  R P Gale; P H Wiernik; H M Lazarus
Journal:  Leukemia       Date:  2014-04-14       Impact factor: 11.528

5.  The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001.

Authors:  Wan-Ling Hsu; Dale L Preston; Midori Soda; Hiromi Sugiyama; Sachiyo Funamoto; Kazunori Kodama; Akiro Kimura; Nanao Kamada; Hiroo Dohy; Masao Tomonaga; Masako Iwanaga; Yasushi Miyazaki; Harry M Cullings; Akihiko Suyama; Kotaro Ozasa; Roy E Shore; Kiyohiko Mabuchi
Journal:  Radiat Res       Date:  2013-02-11       Impact factor: 2.841

6.  Hematopoietic recovery after 10-Gy acute total body radiation.

Authors:  A E Baranov; G D Selidovkin; A Butturini; R P Gale
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

7.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

Review 8.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Authors:  John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

9.  Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Authors:  S M Luger; O Ringdén; M-J Zhang; W S Pérez; M R Bishop; M Bornhauser; C N Bredeson; M S Cairo; E A Copelan; R P Gale; S A Giralt; Z Gulbas; V Gupta; G A Hale; H M Lazarus; V A Lewis; M C Lill; P L McCarthy; D J Weisdorf; M A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.